ACESO LIFE SCI (00474) issues profit warning, expecting annual profit of approximately HKD 336 million, turning loss into profit year-on-year.

20:24 03/08/2026

Xinming Life Science Technology (00474) announced that the group expects to achieve a profit of approximately HKD 336 million for the fiscal year ending March 31, 2026 (the reporting year), compared to a loss of approximately HKD 1.017 billion for the fiscal year ending March 31, 2025. The group's turnaround from loss to profit is primarily due to the gains derived from the sale of a subsidiary during the reporting year.

ACESO LIFE SCI (00474) announced that the Group expects to achieve a profit of approximately HKD 336 million for the year ending March 31, 2026 (reporting year), compared to a loss of approximately HKD 1.017 billion for the year ending March 31, 2025. The turnaround from loss to profit is mainly due to the gains from the sale of a subsidiary during the reporting year.

Zhongji Health (000972.SZ) subsidiary plans to invest in the construction of a direct irrigation sauce repackaging project.

Chengdu Easton Biopharmaceuticals (688513.SH): Nicardipine hydrochloride injection and others are expected to be selected for the national centralized drug procurement.

PRINX CHENGSHAN (01809) has entered into a financing agreement for 1.36 billion yuan and 15 million US dollars.

Zhongji Health (000972.SZ) subsidiary plans to invest in the construction of a direct irrigation sauce repackaging project.

Chengdu Easton Biopharmaceuticals (688513.SH): Nicardipine hydrochloride injection and others are expected to be selected for the national centralized drug procurement.

PRINX CHENGSHAN (01809) has entered into a financing agreement for 1.36 billion yuan and 15 million US dollars.